Evidence map›Paper›PMID 32592040›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2021

Imaging assisted evaluation of antitumor efficacy of a new histone deacetylase inhibitor in the castration-resistant prostate cancer.

Zude Chen, Xiashuang Wang, Xiaoshuang Yang, Yulong Xu, Yu Yang, Hao Wang, Tao Li, Ping Bai, Gengyang Yuan, Huabiao Chen and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 2 countries.

Zude ChenDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Guoxue Xiang 37, Chengdu, 610041, China.
Xiashuang WangAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
Xiaoshuang YangDepartment of Plastic Surgery, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Yulong XuAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
Yu YangAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
Hao WangAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
Tao LiVaccine and Immunotherapy Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.
Ping BaiAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
Gengyang YuanGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
Huabiao ChenVaccine and Immunotherapy Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.
Jing YangAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
Stephanie A FiedlerAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
Robin StriarAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
Daniela R BernalesAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
Robert E KoegelAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
Qi CaoDiagnostic Radiology & Nuclear Medicine, University of Maryland School of Medicine, 670 W. Baltimore Street, Baltimore, MD, 21201, USA.
Chongzhao RanAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
Bo XiangDepartment of Pediatric Surgery, West China Hospital, Sichuan University, Guoxue Xiang 37, Chengdu, 610041, China.
Hong LiDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Guoxue Xiang 37, Chengdu, 610041, China. lihonghxhx@scu.edu.cn.
Changning WangAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA. cwang15@mgh.harvard.edu.
Massachusetts General Hospital · USAthinoula A. Martinos Center for Biomedical Imaging · USHarvard University · USSichuan University · CNUniversity of Maryland, Baltimore · USWest China Hospital of Sichuan University · CNZunyi Medical University · CN

Funding

Carbon-11 Automation Equipment for Human PET Radiotracer ProductionS10OD023517 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI HOOKER, JACOB M. · 2018 to 2018
$502k
NIH HHS S10 OD023517
6 · The paper itself

Abstract

purposeCastration-resistant prostate cancer (CRPC) is the most common cause of death in men. The effectiveness of HDAC inhibitors has been demonstrated by preclinical models, but not in clinical studies, probably due to the ineffectively accumulation of HDACI in prostate cancer cells. The purpose of this work was to evaluate effects of a novel HDACI (CN133) on CRPC xenograft model and 22Rv1 cells, and develops methods, PET/CT imaging, to detect the therapeutic effects of CN133 on this cancer.

methodsWe designed and performed study to compare the effects of CN133 with SAHA on the 22Rv1 xenograft model and 22Rv1 cells. Using PET/CT imaging with [

resultsOur data showed that the CN133 treatment led to a 50% reduction of tumor volume compared to the placebo that was more efficacious than SAHA treatment in this preclinical model. [

conclusionTaken together, these studies provide not only a novel epigenetic approach for prostate cancer therapy but also offering a potential tool, [

Indexed as

Histone Deacetylase InhibitorsProstatic Neoplasms, Castration-ResistantAnimalsCell Line, TumorCell ProliferationHumansMaleMicePositron Emission Tomography Computed TomographyXenograft Model Antitumor AssaysHistone Deacetylase InhibitorsCRPCEpigeneticsHDACPET

Identifiers

PMID32592040
OpenAlexW3037219119

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.